Диссертация (1140941), страница 16
Текст из файла (страница 16)
Neurological Sciences.2008;29(4):285-287.113.Moore RY (1997) Circadian rhythms: basic neurobiology and clinical applications.Annu Rev Med 48, 253–266.114.Morris RW, Lutsch EF. Daily susceptibility rhythm to morphine analgesia. Journalof Pharmaceutical Sciences 58 (3), 374–376, 1969.115.Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritablebowel syndrome: a systematic review. Curr Pharm Des. 2010;16(33):3646-3655.116.Naguib M, Hammond DL, Schmid PG et al. Pharmacological effects of intravenousmelatonin: comparative studies with thiopental and propofol.
Br J Anaesth 2003; 90:504–507.102117.Noseda R, Hernandez A, Valladares L, Mondaca M, Laurido C, Soto-Moyano R.Melatonin-induced inhibition of spinal cord synaptic potentiation in rats is MT2receptordependent. Neurosci Lett 2004; 360:41–44.118.Olde Rikkert MG & Rigaud AS (2001) Melatonin in elderly patients with insomnia.A systematic review. Z Gerontol Geriatr 34, 491–497.119.majorOlie P & Emsley R (2005) Confirmed clinical efficacy of agomelatine (25–50 mg) indepression;tworandomized,double-blindcontrolledstudies.EurNeuropsychopharmacol 15 (Suppl.
3), S416.120.Padhy BM, Kumar VL. Inhibition of Calotropis procera latex-induced inflammatoryhyperalgesia by oxytocin and melatonin. Mediators Inflamm 2005; 2005:360–365.121.Pandi-Perumal SR, Esquifino AI, Cardinali DP, Miller SC & Maestroni GJM (2006)The role of melatonin in immunoenhancement: Potential application in cancer.
Int J ExpPathol 87, 81–87.122.Pandi-Perumal SR, Zisapel N, Srinivasan V & Cardinali DP (2005) Melatonin andsleep in aging population. Exp Gerontol 40, 911–925.123.Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B,HardelandR: Melatonin: Nature’s most versatile biological signal?FEBSJ2006,273:2813–2838.124.Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin,3 mg, is effective for migraine prevention. Neurology 2004; 63:757.125.Peres MFP, Masruha MR, Zukerman E et al.
Potential therapeutic use of melatoninin migraine and other headache disorders. Expert Opin Investig Drugs. 2006;15(4):367375.126.Peres MFP, Rozen TD. Melatonin in the preventive treatment of chronic clusterheadache. Cephalalgia. 2001;21: 993– 5.127.Peres MFP. Melatonin, the pineal gland and their implications for headache.Cephalalgia. 2005;25: 403– 11.103128.Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett JC & Murphy E (1999) Theoncostatic action of melatonin in an ovarian carcinoma cell line.
J Pineal Res 26, 129–136.129.Pevet P, Bothorel B, Slotten H & Saboureau M (2002) The chronobiotic propertiesof melatonin. Cell Tissue Res 309, 183–191.130.Pringsheim T, Magnoux E, Dobson CF et al. Melatonin as adjunctive ther- apy in theprophylaxis of cluster headache: a pilot study. Headache. 2002;42:787-792.131.Ray M, Mediratta PK, Mahajan P, Sharma KK. Evaluation of the role of melatoninin formalin-induced pain response in mice.
Indian J Med Sci 2004; 58:122–130.132.Regodon S, Martin-Palomino P, Fernandez-Montesinos R, Herrera JL, Carrascosa-Salmoral MP, Piriz S, Vadillo S, Guerrero JM & Pozo D (2005) The use of melatonin as avaccine agent. Vaccine 23, 5321–5327.133.Reiter RJ (1998) Oxidative damage in the central nervous system: protection bymelatonin. Prog Neurobiol 56, 359–384.134.Rudra DS, Pal U, Maiti NC, Reiter RJ, Swarnakar S.
Melatonin inhibits matrixmetalloproteinase-9 activity by binding to its active site. Journal of Pineal Research.2013;54:4:398-405.135.Sack RL, Hughes RJ, Edgar DM & Lewy AJ (1997) Sleep-promoting effects ofmelatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep20, 908–915.136.Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatoninin irritable bowel syndrome. J Clin Gastroenterol. 2007;41(1):29- 32.137.Schim JD, Stang P. Overview of pain management.
Pain Pract. 2004 Mar;4 Suppl1:S4-18.138.Schmidt C., Raspe H., Pfingsten M. et al. Back pain in the German adult population.Spine 2007; 37(18):2005-11.139.Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, BruscoLI & Cardinali DP (2001) Lack of changes in serum prolactin, FSH, TSH, and estradiol104after melatonin treatment in doses that improve sleep and reduce benzodiazepineconsumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30, 34–42.140.Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P.
R., & Jacobs, G. A.(1983). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: ConsultingPsychologists Press.141.Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin im- provesabdominal pain in irritable bowel syndrome patients who have sleep disturbances: arandomised, double blind, placebo controlled study. Gut. 2005;54:1402-1407.142.Srinivasan V (2002) Melatonin oxidative stress and neurodegenerative diseases.Indian J Exp Biol 40, 668–679.143.Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R &Cardinali DP (2005) Role of melatonin in neurodegenerative diseases. Neurotox Res 7,293–318.144.Srinivasan V, Smits G, Kayumov L, Pandi-Perumal SR, Cardinali DP & Thorpy MJ(2006) Melatonin in circadian rhythm sleep disorders.
In Neuroendocrine Correlates ofSleep Wakefulness (Cardinali DP & Pandi-Perumal SR, eds), pp. 269–294. Springer, NewYork.145.Srinivasan V., Lauterbach E. , Yu Ho K. Acuña-Castroviejo D. , Zakaria R.,Brzezinski A. Melatonin in Antinociception: Its Therapeutic Applications CurrentNeuropharmacology. 2012;10:167-178.146.Steinhilber D, BrungsM,Werz O,Wiesenberg I, Danielsson C, Kahlen JP, Nayeri S,Schrader M, Carlberg C.
The nuclear receptor for melatonin represses 5-lipoxygenase geneexpression in human B lymphocytes. The Journal of Biological Chemistry 270 (13) 7037–7040, 1995.147.Storr M, Koppitz P, Sibaev A, Saur D, Kurjak M, Franck H, Schusdziarra V &Allescher HD (2002) Melatonin reduces non-adrenergic, non-cholinergic relaxantneurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tractof rodents in vitro. J Pineal Res 33, 101–108.105148.Takahashi T, Sasaki M, Itoh H, Ozone M, Yamadera W, Hayshida K, Ushijima S,Matsunaga N, Obuchi K & Sano H (2000) Effect of 3 mg melatonin on jet lag syndrome inan 8-h eastward flight.
Psychiatry Clin Neurosci 54, 377–378.149.Tan DX, Hardeland R, Manchester LC, Poeggeler B, Lopez-Burillo S, Mayo JC,Sainz RM & Reiter RJ (2003) Mechanistic and comparative studies of melatonin andclassic antioxidants in terms of their interactions with the ABTS cation radical. J PinealRes 34, 249–259.150.Tricoire H, Moller M, Chemineau P & Malpaux B (2003) Origin of cerebrospinalfluid melatonin and possible function in the integration of photoperiod.
Reprod Suppl 61,311–321.151.Tu Y, Sun RQ, Willis WD. Effects of intrathecal injections of melatonin analogs oncapsaicin-induced secondary mechanical allodynia and hyperalgesia in rats. Pain 109 (3),340–350, 2004.152.Ulugol A, Dokmeci D, Guray G, Sapolyo N, Ozyigit F, Tamer M. Antihyperalgesic,but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: possibleinvolvements of the L-arginine-NO pathway and opioid system.
Life Sciences 78 (14),1592–1597, 2006.153.Venkoba rao A, Parvathi Devi S & Srinivasan V (1983) Urinary melatonin indepression. Indian J Psychiatry 25, 167–172.154.Vijayalaxmi Thomas CR Jr, Reiter RJ & Herman TS (2002) Melatonin: from basicresearch to cancer treatment clinics.
J Clin Oncol 20, 2575–2601.155.Wang, S., Zhang, L., Lim, G., Sung, B., Tian, Y., Chou, C.W., Hernstadt, H.,Rusanescu, G., Ma, Y. and Mao, J.A. (2009) Combined Effect of Dextromethorphan andMelatonin on Neuropathic Pain Behavior in Rats. Brain Research, 1288, 42-49.156.Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS. Melatonin inhibitshippocampal long-term potentiation. European Journal of Neurosciences 22 (9), 2231–2237, 2005.106157.Wilhelmsen M., Amirian I., Reiter R. J., Rosenberg J., and Gögenur I.,“Analgesic effects of melatonin: review of current evidence from experimental and clinicalstudies”. Journal of Pineal Research, vol. 51, no. 3, pp.
270–277, 2011.158.Wikner J, Hirsch U, Wetterberg L, Rojdmark S. Fibromyalgia — a syn- dromeassociated with decreased nocturnal melatonin secretion. Clin Endo- crinol (Oxf).1998;49:179-183.159.Wong D., Transfeldt E. Macnab's Backache, 4th Edition - 2007 - LippincottWilliams & Wilkins. 304 p.160.Xu F, Li JC, Ma KC et al. Effects of melatonin on hypothalamic gamma-aminobutyric acid, aspartic acid, glutamic acid, beta-endorphin and serotonin levels inmale mice. Biol Signals 1995; 4:225–231.161.Yu CX, Zhu B, Xu SF, Cao XD, Wu GC. The analgesic effects of periph- eral andcentral administration of melatonin in rats. Eur J Pharmacol.
2000;403:49-53.162.Yongliang Liu, Hongwen Hе, Fang Huang. Melatonin in Pain Modulation:Analgesic or Proalgesic? 2014.163.Zahn, P.K., Lansmann, T., Berger, E., Speckmann, E.J. and Musshoff, U.(2003)Gene Expression and Functional Characterization of Melatonin Receptors in the SpinalCord of the Rat: Implications for Pain Modulation. Journal of Pineal Research, 35, 24-31.164.Zanette S, Vercelino R, Laste G, Rozisky J, Schwertner A, Machado C, Xavier F, deSouza I Cr, Deitos A, Torres I L S, Caumo W.
Melatonin anal- gesia is associated withimprovement of the descending endogenous pain- modulating system in fibromyalgia: aphase II, randomized, double-dum- my, controlled trial. BMC Pharmacology andToxicology. 2014..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
